Showing 3711-3720 of 4063 results for "".
- After Sale of Ellex Medical Lasers, Nova Eye Medical is Formedhttps://modernod.com/news/nova-eye-medical-launches-to-propel-glaucoma-innovation/2477952/Ellex Medical Lasers has completed the sale of its Ellex Lasers & Ultrasound business to Quantel Medical via Lumibird Group SA, and changed its name from Ellex Medical Lasers Limited to Nova Eye Medical Limited. In December 2019, Lumibird Group, the parent company of Quantel Medical, s
- Iveric bio Announces First Patient Dosed in Second Zimura Phase 3 Trial for Treatment of GAhttps://modernod.com/news/iveric-bio-announces-first-patient-dosed-in-second-zimura-phase-3-trial-for-treatment-of-ga/2477951/Iveric bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (
- Envision Conference Goes Virtual This Augusthttps://modernod.com/news/envision-conference-goes-virtual-this-august/2477945/Envision has announced that it is shifting the format for Envision Conference East to a live-stream webinar occurring August 14-15, 2020. In addition to creating a safer environment in the midst of the COVID-19 crisis, the virtual format will facilitate participation in
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r
- Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen for the Treatment of Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reinitiates-patient-enrollment-in-clinical-study-of-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477911/Lineage Cell Therapeutics announced that it has restarted patient enrollment in a phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD),
- Two ARVO Papers Provide New Insights for Contact Lens-Based Myopia Management with Childrenhttps://modernod.com/news/two-arvo-papers-provide-new-insights-for-contact-lens-based-myopia-management-with-children/2477900/Two scientific papers being presented as part of the ARVO (Association for Research in Vision and Ophthalmology) 2020 virtual conference proceedings provide eye care professionals (ECPs) with new insights to aid contact lens-based myopia management with children. ReCSS Study Ex
- Johnson & Johnson Vision Presents Myopia Research Findings at ARVOhttps://modernod.com/news/johnson-johnson-vision-presents-myopia-research-findings-reports-contact-lens-iol-and-equipment-data-at-arvo-annual-meeting/2479519/Johnson & Johnson Vision will present the first clinical research findings from its comprehensive myopia clinical research program with the Singapore Eye Research Institute (SERI) and Singapore National Eye Centre (SNEC), as well as new data on contact lens and surgical innovations, at the 20
- Zeiss Announces 3 Million Eyes Treated With SMILEhttps://modernod.com/news/zeiss-announces-3-million-eyes-treated-with-smile/2477881/Zeiss Medical Technology announced a new milestone with more than 3 million treated eyes with SMILE in more than 1,000 clinics worldwide. SMILE, which became commercially available in the United States in 2017, is a minimally-invasive corneal refractive procedure performed by using the Vi
- Novartis Provides Update On Use and Safety of Beovu (brolucizumab)https://modernod.com/news/novartis-provides-update-on-use-and-safety-of-beovu-brolucizumab/2477873/An internal review of post-marketing safety case reports of brolucizumab (Beovu; Novartis) has confirmed a rare occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion. Following FDA approval of Beovu in October 2019, Novartis rece